Opko Health SEC Filings

OPKO Health (OPK) insider trading report: Phillip Frost, M.D., who serves as CEO, Chairman, director and a 10% owner of OPKO Health, reported a series of open-market purchases of the company’s common stock. On 11/20/2025, he bought a total of 580,000 common shares in multiple trades at prices ranging from $1.32 to $1.35 per share, all reported as indirect ownership through Frost Gamma Investments Trust. After these transactions, one reported indirect position shows 216,126,448 shares beneficially owned. The filing also lists 3,568,951 shares held directly and an additional 30,127,177 shares held indirectly through Frost Nevada Investments Trust. The report states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.

OPKO Health (OPK) insider Phillip Frost, M.D., who serves as CEO, Chairman and a 10% owner, reported multiple open market purchases of the company’s common stock. On 11/19/2025, he bought a total of 580,000 shares in several transactions at prices ranging from $1.28 to $1.32 per share. Following these transactions, he was reported as indirectly beneficially owning 215,546,448 shares through Frost Gamma Investments Trust, with additional holdings of 3,568,951 shares directly and 30,127,177 shares indirectly through Frost Nevada entities, while expressly disclaiming beneficial ownership beyond his pecuniary interest.

OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D. reported multiple purchases of OPKO common stock on 11/18/2025. The transactions, coded as open-market or private purchases, ranged from $1.245 to $1.29 per share across several small trades.

Following these transactions, Frost is shown as beneficially owning 214,966,448 OPKO shares indirectly, as noted in a footnote describing Frost Gamma Investments Trust and related entities. Additional holdings of 3,568,951 shares are listed as directly owned, and 30,127,177 shares as indirectly owned through Frost Nevada Investments Trust, with both positions also accompanied by detailed ownership-disclaimer language. Frost is identified as a director, 10% owner, CEO and Chairman of OPKO Health.

OPKO Health (OPK): Phillip Frost, M.D., the company’s CEO, Chairman, Director and a 10% owner, reported an open‑market purchase of 150,000 shares of common stock on 10/31/2025 at a weighted average price of $1.4229. The price reflects multiple trades between $1.415 and $1.4299.

Following the transaction, reported beneficial ownership includes 3,568,951 shares direct, 214,386,448 shares indirect held by Frost Gamma Investments Trust, and 30,127,177 shares indirect held by Frost Nevada Investments Trust. The filing notes trust structures and standard beneficial ownership disclaimers.

OPKO Health filed its Q3 2025 10‑Q, reporting a profitable quarter driven by an asset sale. Total revenue was $151.7 million versus $173.6 million a year ago, with services at $95.2 million, products at $37.7 million, and transfer of intellectual property and other at $18.7 million. Operating income rose to $48.1 million from $14.2 million, aided by a $101.6 million gain on the sale of BioReference’s oncology diagnostics business to Labcorp.

Net income was $21.6 million (basic EPS $0.03), compared to $24.9 million last year. For the nine months, revenue was $458.4 million and net loss was $194.4 million, reflecting higher interest expense and the absence of prior‑year gains. Cash, cash equivalents and current restricted cash were $415.2 million, with total assets of $2.00 billion and total liabilities of $690.0 million.

The Labcorp oncology transaction delivered $192.5 million in consideration, including $173.3 million in cash and $19.2 million in escrow, plus up to $32.5 million in contingent consideration. OPKO continued its repurchase program, buying 24.3 million shares year‑to‑date for approximately $33.5 million, bringing total program spend to about $73.8 million. As of October 17, 2025, 767,701,280 common shares were outstanding. The company disclosed a foreign tax assessment of approximately $246 million; it has recorded a $9.9 million accrual related to uncertain tax positions.

OPKO Health (OPK) furnished an 8-K stating it issued a press release with operating and financial highlights for the quarter ended September 30, 2025. The release also explains how to access the company’s conference call covering third-quarter results and provides financial guidance. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and a copy of the press release is attached as Exhibit 99.1.

Phillip Frost M.D. and related entities reported multiple dispositions of OPKO HEALTH, INC. (OPK) common stock on 08/18/2025. The Form 4 shows a reported sale (transaction code G) of 440,000 shares for $0 and additional dispositions of 3,568,951 shares. Following the reported transactions, the filing lists 214,236,448 shares and 30,127,177 shares held indirectly by affiliated trusts and entities, with ownership described in footnotes clarifying trustee/beneficiary relationships. The filing is signed by Phillip Frost, M.D., individually and as trustee, indicating the report covers both his individual and related trust holdings.

Phillip Frost, M.D., in his capacities as CEO & Chairman, director and reported 10% owner, disclosed multiple changes in his OPKO Health (OPK) holdings. The filing shows on 08/08/2025 a purchase of 675,000 shares at $1.32 per share and a reported disposition of 3,568,951 shares. Following the reported transactions the Form lists indirect beneficial ownership amounts of 214,676,448 shares and 30,127,177 shares, each referenced to separate footnotes.

The footnotes explain these shares are held through Frost-controlled entities and trusts (Frost Gamma Investments Trust and Frost Nevada Investments Trust) with Dr. Frost acting as trustee or related party; the filing states he disclaims beneficial ownership except to the extent of any pecuniary interest. The report is a Section 16 Form 4 disclosure of insider activity and trust relationships only.